Item 2.02 - Results of Operations and Financial Condition: Waters Corporation announced its financial results for the quarter and year ended December 31, 2025 on February 9, 2026 Press Release Furnished as Exhibit 99.1: A copy of the earnings press release containing the detailed financial results is attached to this 8-K filing Non-Filed Status: The information in Item 2.02 and the attached press…

Our analysis rates this filing CAUTIOUS. Waters presents a mixed but cautiously concerning profile. The company delivered solid 2025 results with 7% revenue growth and 11% EPS growth, supported by strong recurring revenue momentum and broad geographic diversification. Management tone is optimistic…

Concern level: HIGH (6.2/10). Key factors: BD Biosciences acquisition integration execution risk - $3B+ revenue contribution with synergies described as 'in progress' rather than realized; material debt financing increases leverage; Organic growth deceleration - 2026 guidance of 5.5%-7.0% organic growth versus 7% achieved in 2025, indicating slowing underlying business momentum; Q1 2026 EPS…

Notable risk changes: BD Biosciences acquisition closing today (Feb 9, 2026) - transforms Waters into $6.4B+ revenue company with significant integration execution risk and synergy realization uncertainty; Full-year 2026 guidance includes $3B acquired business contribution but only 5.5%-7.0% organic growth guidance, suggesting mature/slowing organic growth trajectory despite 7% growth in 2025; Q1 2026 non-GAAP EPS…

Q4 2025 sales of $932 million landed at high-end of reported sales growth guidance range.

The model predicts WAT will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.